Hepcludex (Bulevirtide)

Hepcludex is prescribed for patients with chronic hepatitis D virus (HDV) infection, often in combination with standard hepatitis B therapy.

• Treatment of chronic HDV infection in adults.
• Use as an adjunct to nucleos(t)ide analogues for hepatitis B virus co‑infection.
• Management of patients with detectable HDV RNA who have not responded adequately to existing therapies.
• Consideration in liver transplant candidates with HDV to reduce viral load pre‑operatively.

The safety profile of Hepcludex includes both frequently observed and less common adverse events.

Common

• Injection site reactions such as pain, redness, or swelling.
• Mild headache or fatigue.
• Transient elevation of liver enzymes (ALT/AST).
• Nausea or mild gastrointestinal discomfort.

Serious

• Severe hypersensitivity reactions, including rash or anaphylaxis.
• Significant liver injury manifested by marked ALT/AST increase.
• Thrombocytopenia or other hematologic abnormalities.

Clinicians should evaluate several precautionary factors before initiating Hepcludex therapy.

• Assess liver function tests and baseline viral load.
• Avoid use in patients with known hypersensitivity to bulevirtide.
• Monitor for signs of hepatic decompensation during treatment.
• Consider pregnancy status; safety data are limited.
• Evaluate renal function, although no dose adjustment is required.
• Use caution in patients receiving other hepatotoxic agents.
• Educate patients on proper subcutaneous injection technique.

Potential drug interactions with Hepcludex are limited but should be reviewed.

Avoid

• Co‑administration with strong NTCP inhibitors that may reduce bulevirtide efficacy.
• Concurrent use of investigational antiviral agents without clinical guidance.

Use with caution

• Combination with nucleos(t)ide analogues for HBV; monitor liver enzymes.
• Concurrent hepatotoxic medications such as certain antifungals or antiretrovirals.
• Vaccinations administered shortly before or after injection; observe for enhanced local reactions.